News
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 to $346.
Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...
Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.
Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results